Nose to Brain Delivery

Message from the Guest Editors

The blood-brain barrier (BBB) separates the central nervous system (CNS) from general circulation. Drugs targeting the brain represent a remarkable problem, owing to BBB, which does not allow most drugs to pass through it. The use of a nose-to-brain delivery route is an important and noninvasive method of drug delivery to solve this problem and bypass the BBB. Different strategies have been developed to enhance nose-to-brain drug delivery. In fact, it is well-known that an intranasal direct anatomical connection between the nasal cavity and the CNS exists, which suggests the development of nasal formulations for brain targeting of drugs. The design and preparation of nasal formulations involve the development of polymeric pharmaceutical platforms able to interact with nasal mucosa: Bioadhesion and penetration enhancement through nasal mucosa layers are the first and most important characteristics that these systems must have. The development of new nasal systems represents a great challenge in the field of controlled drug targeting and delivery.

This Special Issue has the aim of highlighting current progress in the use of the nasal route for brain targeting.

mdpi.com/si/10173
**Editor-in-Chief**

**Prof. Dr. Yvonne Perrie**  
Chair in Drug Delivery,  
Strathclyde Institute of Pharmacy and Biomedical Sciences,  
University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK

---

**Message from the Editor-in-Chief**

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

**Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Covered by *Scopus*: papers published between 2013 and 2015 have been cited 3.83 times, on average, in 2016 (CiteScore 2016).

**Rapid publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 19 days after submission; acceptance to publication is undertaken in 7.2 days (median values for papers published in this journal in 2017).

**Contact us**

*Pharmaceutics*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
www.mdpi.com

mdpi.com/journal/pharmaceutics  
pharmaceutics@mdpi.com  
@MDPipharma